Hospital
ST. Mary Medical Center
ST. Mary Medical Center was paid $52.36M by Medicaid between Jan 2018 and Dec 2024, across 380 billing codes. Its largest line is 0450, Emergency room services — 12% of everything it billed.
33Billing provider infoST. MARY MEDICAL CENTER
APPLE VALLEY, CA 92307
APPLE VALLEY, CA 92307
33aNPI1710109186assigned 05/03/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$52.36M
24GClaims1,987,799
24DCodes billed380
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#59 of 410
Median peer was paid$6.90M
This provider vs. median7.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 278,217 | $6.73M | |
| 2019 | 296,662 | $7.66M | |
| 2020 | 258,137 | $6.56M | |
| 2021 | 245,837 | $6.31M | |
| 2022 | 281,063 | $7.53M | |
| 2023 | 327,818 | $8.72M | |
| 2024incomplete | 300,065 | $8.85M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 12% | 130,142 | 113,500 | $6.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 85,455 | 76,220 | $4.22M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 17,957 | 17,267 | $2.66M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 11,023 | 10,683 | $2.06M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.0% | 7,118 | 3,580 | $1.56M |
| 80053 | Comprehensive metabolic panel | 2.8% | 103,067 | 91,282 | $1.47M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 26,431 | 24,957 | $1.45M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.8% | 11,476 | 11,110 | $1.45M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 49,802 | 45,427 | $1.34M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 123,339 | 106,949 | $1.26M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.3% | 12,931 | 12,550 | $1.20M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 41,465 | 34,637 | $1.10M |
368 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.9% | 17,957 | $978K |
| Z7502 | 1.6% | 22,435 | $844K | |
| 99285 | Emergency room visit (most serious) | 1.5% | 7,541 | $777K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 21,507 | $756K |
| 15275 | 1.4% | 647 | $740K | |
| 84484 | 1.4% | 51,660 | $737K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.4% | 3,896 | $708K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 9,222 | $630K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 3,519 | $583K |
| 99499 | 1.1% | 6,859 | $564K | |
| 84702 | 1.1% | 34,857 | $552K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 10,498 | $544K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 28,751 | $527K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17,047 | $508K |
| 0206 | <1% | 52 | $393K | |
| 11043 | <1% | 954 | $357K | |
| 0360 | <1% | 2,514 | $354K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,596 | $352K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,012 | $346K |
| 93975 | <1% | 1,770 | $343K | |
| 83690 | <1% | 37,146 | $342K | |
| 71045 | Radiologic examination, chest; single view | <1% | 35,870 | $340K |
| 93971 | <1% | 3,670 | $340K | |
| 72131 | <1% | 1,977 | $327K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,350 | $323K |
| 83880 | <1% | 15,545 | $321K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,830 | $290K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15,009 | $290K |
| 81001 | <1% | 61,206 | $278K | |
| 99284 | Emergency room visit (serious) | <1% | 3,772 | $275K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,462 | $275K |
| G0378 | Hospital observation service, per hour | <1% | 5,637 | $271K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 747 | $260K |
| 99070 | <1% | 138,718 | $255K | |
| Q4133 | Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure) | <1% | 363 | $245K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,882 | $243K |
| 76801 | <1% | 4,696 | $237K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,760 | $229K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,023 | $207K |
| 87040 | <1% | 12,626 | $204K | |
| 70496 | <1% | 1,493 | $203K | |
| 49083 | <1% | 1,848 | $195K | |
| 93970 | <1% | 1,217 | $194K | |
| 83605 | <1% | 12,320 | $185K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,072 | $180K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,765 | $179K |
| 70486 | <1% | 1,180 | $177K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,660 | $173K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,896 | $171K |
| 0761 | <1% | 5,073 | $168K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,038 | $167K |
| Z9725 | <1% | 3,718 | $160K | |
| 93458 | <1% | 103 | $159K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,415 | $159K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 712 | $156K |
| 70498 | <1% | 1,549 | $152K | |
| J3490 | Unclassified drugs | <1% | 81,348 | $145K |
| 11044 | <1% | 127 | $130K | |
| 85379 | <1% | 9,679 | $130K | |
| 87631 | <1% | 2,647 | $129K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,225 | $128K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 569 | $125K |
| 83735 | <1% | 15,494 | $124K | |
| 0710 | <1% | 4,515 | $124K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,062 | $116K |
| 85610 | <1% | 21,903 | $115K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,381 | $114K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,365 | $112K |
| 85730 | <1% | 15,961 | $110K | |
| 0240U | <1% | 906 | $109K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 604 | $107K |
| 84703 | <1% | 10,099 | $103K | |
| 73630 | <1% | 4,610 | $100K | |
| 90715 | <1% | 2,924 | $97K | |
| 73130 | <1% | 4,183 | $97K | |
| 76770 | <1% | 1,423 | $95K | |
| 73610 | <1% | 3,906 | $91K | |
| 73562 | <1% | 4,108 | $86K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,932 | $81K |
| 73030 | <1% | 3,339 | $80K | |
| 74018 | <1% | 4,814 | $80K | |
| 0762 | <1% | 1,450 | $77K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,986 | $76K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 374 | $76K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,113 | $74K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,076 | $72K |
| 82948 | <1% | 13,992 | $71K | |
| 82962 | <1% | 10,266 | $67K | |
| 84439 | <1% | 5,980 | $67K | |
| 86901 | <1% | 10,660 | $66K | |
| 73110 | <1% | 2,801 | $65K | |
| 93454 | <1% | 39 | $64K | |
| 72100 | <1% | 2,338 | $60K | |
| 70491 | <1% | 275 | $56K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 1,871 | $56K |
| 96367 | <1% | 1,544 | $54K | |
| 99152 | <1% | 1,689 | $53K | |
| 87186 | <1% | 3,969 | $51K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,191 | $51K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,173 | $50K |
| 76870 | <1% | 935 | $49K | |
| 86141 | <1% | 5,754 | $49K | |
| 96376 | <1% | 2,324 | $48K | |
| 86850 | <1% | 5,392 | $48K | |
| Z7610 | <1% | 10,050 | $47K | |
| 73080 | <1% | 1,844 | $45K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 988 | $44K |
| 86900 | <1% | 10,613 | $44K | |
| 73502 | <1% | 1,552 | $42K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,078 | $41K |
| 86923 | <1% | 274 | $41K | |
| 82805 | <1% | 1,095 | $40K | |
| 93017 | <1% | 717 | $39K | |
| 85027 | <1% | 4,995 | $38K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 332 | $37K |
| 73590 | <1% | 2,100 | $37K | |
| 15271 | <1% | 30 | $37K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,486 | $36K |
| 73090 | <1% | 1,864 | $35K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,507 | $35K |
| 71250 | <1% | 192 | $35K | |
| 87077 | <1% | 4,595 | $34K | |
| 72040 | <1% | 1,365 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,950 | $32K |
| 74021 | <1% | 1,360 | $32K | |
| 81025 | <1% | 4,411 | $31K | |
| 99217 | <1% | 390 | $31K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14,459 | $31K |
| 82550 | <1% | 3,728 | $31K | |
| 80061 | Lipid panel | <1% | 2,517 | $30K |
| 88304 | <1% | 2,355 | $29K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,970 | $28K |
| 81003 | <1% | 9,402 | $28K | |
| 72128 | <1% | 227 | $28K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 121 | $28K |
| 59025 | Fetal non-stress test | <1% | 1,367 | $27K |
| 82728 | <1% | 1,692 | $27K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 11,089 | $26K |
| 82803 | <1% | 927 | $25K | |
| 71101 | <1% | 619 | $24K | |
| 76937 | <1% | 1,574 | $23K | |
| V2632 | Posterior chamber intraocular lens | <1% | 216 | $23K |
| 87070 | <1% | 2,240 | $22K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,460 | $22K |
| 47562 | <1% | 68 | $22K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 594 | $21K |
| 12001 | <1% | 1,127 | $21K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 346 | $21K |
| 87210 | <1% | 3,308 | $20K | |
| 87430 | <1% | 1,406 | $17K | |
| 80076 | <1% | 1,701 | $17K | |
| 82010 | <1% | 1,567 | $17K | |
| 99221 | <1% | 153 | $17K | |
| 82140 | <1% | 1,167 | $16K | |
| J1815 | Injection, insulin, per 5 units | <1% | 5,312 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,512 | $16K |
| 87081 | <1% | 2,083 | $16K | |
| V5008 | Hearing screening | <1% | 364 | $15K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,796 | $15K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,394 | $14K |
| 10060 | <1% | 813 | $14K | |
| 87807 | <1% | 2,030 | $14K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,085 | $14K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,599 | $14K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 3,020 | $14K |
| 83615 | <1% | 1,762 | $14K | |
| 87205 | <1% | 2,719 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,515 | $13K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 201 | $13K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 39 | $13K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,991 | $13K |
| 0250 | <1% | 4,103 | $12K | |
| 99199 | Unlisted special service, procedure or report | <1% | 294 | $12K |
| 84100 | <1% | 2,599 | $12K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,324 | $12K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,151 | $12K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 736 | $12K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,084 | $12K |
| 12011 | <1% | 581 | $12K | |
| 73060 | <1% | 672 | $12K | |
| 59425 | <1% | 192 | $11K | |
| 29515 | <1% | 1,231 | $11K | |
| 29125 | <1% | 1,646 | $11K | |
| 92523 | <1% | 146 | $11K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,433 | $10K |
| 99153 | Mod sedat endo service >5yrs | <1% | 991 | $10K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 636 | $10K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,010 | $10K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,071 | $10K |
| 76999 | <1% | 102 | $9K | |
| 87075 | <1% | 939 | $9K | |
| 73552 | <1% | 471 | $9K | |
| 97533 | <1% | 486 | $9K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 983 | $9K |
| 88342 | <1% | 348 | $9K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,418 | $8K |
| 0361 | <1% | 66 | $8K | |
| 0272 | <1% | 671 | $8K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,642 | $7K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,789 | $7K |
| 85652 | <1% | 2,263 | $7K | |
| 84550 | <1% | 1,222 | $7K | |
| 87147 | <1% | 1,306 | $7K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 302 | $7K |
| 71020 | <1% | 266 | $7K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 143 | $7K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,121 | $6K |
| 82731 | <1% | 148 | $6K | |
| 73140 | <1% | 401 | $6K | |
| 82570 | <1% | 1,051 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 89 | $5K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,303 | $5K |
| 94664 | <1% | 754 | $5K | |
| 70360 | <1% | 328 | $5K | |
| 72070 | <1% | 190 | $5K | |
| 96368 | <1% | 248 | $5K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,590 | $5K |
| 94799 | <1% | 175 | $5K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,858 | $5K |
| Z6410 | <1% | 540 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $4K |
| 72170 | <1% | 249 | $4K | |
| 74019 | <1% | 189 | $4K | |
| 12002 | <1% | 250 | $4K | |
| 0270 | <1% | 1,859 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 488 | $4K |
| Z6500 | <1% | 27 | $4K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 26 | $4K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 110 | $4K |
| 97161 | <1% | 115 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,623 | $4K |
| 97116 | <1% | 280 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,353 | $3K |
| 29505 | <1% | 345 | $3K | |
| 85018 | <1% | 1,071 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,021 | $3K |
| 36600 | <1% | 253 | $3K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 589 | $3K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 326 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 80 | $3K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 616 | $3K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,788 | $3K |
| C1769 | Guide wire | <1% | 156 | $2K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 99 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 91 | $2K |
| 85049 | <1% | 992 | $2K | |
| 72072 | <1% | 72 | $2K | |
| 71010 | <1% | 139 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 637 | $2K |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 679 | $2K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 827 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 432 | $2K |
| 86308 | <1% | 280 | $2K | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 237 | $2K |
| 84156 | <1% | 710 | $2K | |
| 82077 | <1% | 45 | $2K | |
| 94760 | <1% | 456 | $2K | |
| 84132 | <1% | 337 | $2K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 192 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 77 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,056 | $1K |
| 58558 | <1% | 12 | $1K | |
| 85384 | <1% | 111 | $1K | |
| 74022 | <1% | 28 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 94 | $1K |
| 94729 | <1% | 28 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,807 | $1K |
| 0353U | <1% | 25 | $1K | |
| 94726 | <1% | 28 | $1K | |
| 29105 | <1% | 132 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 310 | $1K |
| 51702 | <1% | 83 | $1K | |
| 82330 | <1% | 58 | $996.86 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 65 | $980.53 |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $974.05 |
| 88307 | <1% | 26 | $955.36 | |
| 86920 | <1% | 14 | $952.90 | |
| 74000 | <1% | 58 | $935.54 | |
| 97799 | <1% | 92 | $918.87 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 624 | $870.03 |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 16 | $865.16 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 132 | $861.23 |
| A4217 | Sterile water/saline, 500 ml | <1% | 152 | $855.90 |
| 74020 | <1% | 28 | $849.52 | |
| 80074 | <1% | 12 | $797.42 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 664 | $756.34 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 684 | $740.66 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 27 | $735.95 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 955 | $709.59 |
| 0637 | <1% | 452 | $698.86 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 572 | $660.32 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 12 | $658.20 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 210 | $643.95 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 20 | $595.20 |
| 93990 | <1% | 14 | $583.40 | |
| 82150 | <1% | 72 | $574.45 | |
| 82248 | <1% | 84 | $562.55 | |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 35 | $561.50 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 255 | $544.18 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,675 | $535.00 |
| 0391 | <1% | 18 | $488.38 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 130 | $479.54 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 254 | $451.70 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 158 | $447.19 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 16 | $444.84 |
| 84145 | <1% | 25 | $439.34 | |
| 0258 | <1% | 710 | $427.91 | |
| 0636 | <1% | 147 | $423.64 | |
| 82272 | <1% | 345 | $422.44 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 257 | $386.41 |
| 99156 | <1% | 17 | $381.66 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 65 | $360.66 |
| 90384 | <1% | 13 | $358.01 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 99 | $342.33 |
| 88302 | <1% | 34 | $335.58 | |
| Z6400 | <1% | 27 | $294.35 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,645 | $285.56 |
| 84295 | <1% | 45 | $267.51 | |
| 11045 | <1% | 188 | $247.55 | |
| 83550 | <1% | 30 | $220.95 | |
| 73000 | <1% | 12 | $219.67 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 95 | $217.68 |
| 82553 | <1% | 15 | $216.62 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 123 | $212.14 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,331 | $205.13 |
| 73120 | <1% | 13 | $203.19 | |
| 82947 | <1% | 42 | $202.80 | |
| 73660 | <1% | 13 | $202.13 | |
| 83540 | <1% | 31 | $187.75 | |
| 82247 | <1% | 26 | $178.23 | |
| 94200 | <1% | 13 | $169.32 | |
| 36410 | <1% | 59 | $168.98 | |
| 0410 | <1% | 33 | $146.17 | |
| 82270 | <1% | 44 | $140.13 | |
| 86592 | <1% | 26 | $130.58 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 65 | $130.30 |
| 82607 | <1% | 14 | $115.85 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 38 | $111.07 |
| 29130 | <1% | 15 | $84.00 | |
| 87340 | <1% | 12 | $82.17 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 30 | $63.82 |
| 83986 | <1% | 13 | $59.36 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 41 | $59.27 |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | <1% | 190 | $49.61 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 70 | $47.94 |
| J1921 | Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg | <1% | 20 | $45.88 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 61 | $28.25 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 114 | $28.02 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 26 | $19.64 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 75 | $18.04 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 17 | $14.93 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 32 | $0.00 |
| 0460 | 0% | 32 | $0.00 | |
| 0730 | 0% | 64 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 69 | $0.00 |
| 0300 | 0% | 82 | $0.00 | |
| 84112 | 0% | 20 | $0.00 | |
| 76818 | 0% | 55 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 58 | $0.00 |
| 0301 | 0% | 82 | $0.00 | |
| 94762 | 0% | 50 | $0.00 | |
| 0305 | 0% | 27 | $0.00 | |
| 0306 | 0% | 46 | $0.00 | |
| 80050 | General health panel | 0% | 260 | $0.00 |
| A9270 | Non-covered item or service | 0% | 321 | $0.00 |
| 0324 | 0% | 78 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 32 | $0.00 |
| 36416 | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Parent organizationST JOSEPH HEALTH SYSTEM
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.